New hope for tough stomach cancers: major trial tests Next-Generation drug
NCT ID NCT07152405
Summary
This study is testing a new drug called BL-M07D1 for people with advanced HER2-positive stomach or gastroesophageal cancer that has worsened after their first treatment. It will compare the new drug against standard chemotherapy to see which is better at helping patients live longer and control their cancer. The trial aims to enroll 490 adults and will closely monitor how well the treatment works and its side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, Heilongjiang, China
Contact
Conditions
Explore the condition pages connected to this study.